PHYSIOLOGICAL-ROLE FOR ENHANCED RENAL THROMBOXANE PRODUCTION IN MURINE LUPUS NEPHRITIS

被引:24
作者
SPURNEY, RF
BERNSTEIN, RJ
RUIZ, P
PISETSKY, DS
COFFMAN, TM
机构
[1] DUKE UNIV, MED CTR, DIV RHEUMATOL, DURHAM, NC 27710 USA
[2] VET ADM MED CTR, DURHAM, NC 27705 USA
[3] UNIV MIAMI, SCH MED, DEPT PATHOL, MIAMI, FL 33101 USA
关键词
D O I
10.1016/0090-6980(91)90090-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To investigate the physiologic significance of enhanced renal thromboxane production in murine lupus nephritis, we measured renal hemodynamics and eicosanoid production in MRL-lpr/lpr mice from 8 to 20 weeks of age. Over this age range, MRL-lpr/lpr mice develop an autoimmune disease with nephritis similar to human systemic lupus erythematosus (SLE). In these studies, glomerular filtration rate (GFR) and PAH clearance (C(PAH)) decreased progressively with age in MRL-lpr/lpr mice, but not in controls. This impairment of renal hemodynamics was associated with increased renal thromboxane production, as well as increased excretion of both thromboxane B2 (TxB2) and 2,3-dinor TxB2 in urine. There was an inverse correlation between renal thromboxane production in MRL-lpr/lpr mice and both GFR and C(PAH). Furthermore, there were positive correlations between thromboxane production by the kidney and both the severity of renal histopathology and serum anti-DNA antibody levels measured in individual animals. Enhanced urinary excretion of TxB2 and the development of renal dysfunction also coincided temporally with the appearance of increased levels of interleukin 1-beta (IL-1-beta) mRNA in renal cortex. Acute administration of the specific thromboxane receptor antagonist GR32191 to MRL-lpr/lpr mice restored GFR to normal in early stages of the autoimmune disease. However, in animals with more advanced nephritis, the effect of acute thromboxane receptor blockade on renal hemodynamics was less marked. We conclude that thromboxane A2 is an important mediator of reversible renal hemodynamic impairment in murine lupus, especially in the early phase of disease.
引用
收藏
页码:15 / 28
页数:14
相关论文
共 38 条
[1]  
BAYLIS C, 1987, RENAL PHYSIOL BIOCH, V10, P110
[2]  
BENIGNI A, 1989, AM J PHYSIOL, V26, pF77
[3]  
BOSWELL JM, 1988, J IMMUNOL, V141, P118
[4]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[5]  
BRENNAN DC, 1989, J IMMUNOL, V143, P3470
[6]   MEASUREMENT OF RENAL AND NONRENAL EICOSANOID SYNTHESIS [J].
CATELLA, F ;
NOWAK, J ;
FITZGERALD, GA .
AMERICAN JOURNAL OF MEDICINE, 1986, 81 (2B) :23-29
[7]  
CENSINI S, 1989, LYMPHOKINE RES, V8, P107
[8]   ISOLATION OF BIOLOGICALLY-ACTIVE RIBONUCLEIC-ACID FROM SOURCES ENRICHED IN RIBONUCLEASE [J].
CHIRGWIN, JM ;
PRZYBYLA, AE ;
MACDONALD, RJ ;
RUTTER, WJ .
BIOCHEMISTRY, 1979, 18 (24) :5294-5299
[9]   CHRONIC THROMBOXANE INHIBITION PRESERVES FUNCTION OF REJECTING RAT RENAL-ALLOGRAFTS [J].
COFFMAN, TM ;
RUIZ, P ;
SANFILIPPO, F ;
KLOTMAN, PE .
KIDNEY INTERNATIONAL, 1989, 35 (01) :24-30
[10]   COMPARISON OF THE ACTIONS OF U-46619, A PROSTAGLANDIN H2-ANALOGUE, WITH THOSE OF PROSTAGLANDIN-H2 AND THROMBOXANE-A2 ON SOME ISOLATED SMOOTH-MUSCLE PREPARATIONS [J].
COLEMAN, RA ;
HUMPHREY, PPA ;
KENNEDY, I ;
LEVY, GP ;
LUMLEY, P .
BRITISH JOURNAL OF PHARMACOLOGY, 1981, 73 (03) :773-778